GB0008710D0 - Therapeutic compounds - Google Patents

Therapeutic compounds

Info

Publication number
GB0008710D0
GB0008710D0 GBGB0008710.6A GB0008710A GB0008710D0 GB 0008710 D0 GB0008710 D0 GB 0008710D0 GB 0008710 A GB0008710 A GB 0008710A GB 0008710 D0 GB0008710 D0 GB 0008710D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic compounds
therapeutic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0008710.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Priority to GBGB0008710.6A priority Critical patent/GB0008710D0/en
Publication of GB0008710D0 publication Critical patent/GB0008710D0/en
Priority to AU2001244399A priority patent/AU2001244399A1/en
Priority to US10/257,058 priority patent/US6984626B2/en
Priority to PCT/GB2001/001549 priority patent/WO2001077144A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0008710.6A 2000-04-07 2000-04-07 Therapeutic compounds Ceased GB0008710D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB0008710.6A GB0008710D0 (en) 2000-04-07 2000-04-07 Therapeutic compounds
AU2001244399A AU2001244399A1 (en) 2000-04-07 2001-04-04 Gamma-secretase inhibitors
US10/257,058 US6984626B2 (en) 2000-04-07 2001-04-04 Gamma-secretase inhibitors
PCT/GB2001/001549 WO2001077144A1 (en) 2000-04-07 2001-04-04 Gamma-secretase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008710.6A GB0008710D0 (en) 2000-04-07 2000-04-07 Therapeutic compounds

Publications (1)

Publication Number Publication Date
GB0008710D0 true GB0008710D0 (en) 2000-05-31

Family

ID=9889526

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0008710.6A Ceased GB0008710D0 (en) 2000-04-07 2000-04-07 Therapeutic compounds

Country Status (4)

Country Link
US (1) US6984626B2 (en)
AU (1) AU2001244399A1 (en)
GB (1) GB0008710D0 (en)
WO (1) WO2001077144A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2004026331A1 (en) * 2002-09-17 2004-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Peptides inhibiting specific cleaving activities of presenilins
BRPI0407597A (en) * 2003-02-18 2006-02-21 Roskamp Res Llc Anti-angiogenic and anti-tumor properties of beta and gamma secretase inhibitors
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
CA2554779A1 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
EP2369014A1 (en) 2004-02-03 2011-09-28 The Regents Of The University Of Michigan Office Of Technology Transfer Compositions and methods for characterizing, regulating, diagnosing and treating cancer
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
EP1945754B1 (en) 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1998785A4 (en) * 2006-02-21 2009-06-17 Univ Michigan Hedgehog signaling pathway antagonist cancer treatment
WO2011053822A2 (en) 2009-11-01 2011-05-05 The Brigham And Women's Hospital, Inc. Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
US8133857B2 (en) * 2006-03-07 2012-03-13 The Brigham and Women's FHospital, Inc. NOTCH inhibition in the treatment of atherosclerosis
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
JP5523107B2 (en) 2006-11-30 2014-06-18 プロビオドルグ エージー Novel inhibitors of glutaminyl cyclase
US8148147B2 (en) 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5667440B2 (en) 2007-04-18 2015-02-12 プロビオドルグ エージー Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009035522A1 (en) * 2007-09-14 2009-03-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
CN104188971B (en) 2007-12-21 2017-05-03 配体药物公司 Selective androgen receptor modulators (sarms) and uses thereof
CA2743436C (en) 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
US20120129189A1 (en) * 2009-07-17 2012-05-24 Chulan Kwon Methods of Controlling Cell Proliferation
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
KR101790806B1 (en) 2010-03-10 2017-11-20 프로비오드룩 아게 Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
TWI530489B (en) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds
US9629891B2 (en) 2011-10-17 2017-04-25 Nationwide Children's Hospital, Inc. Products and methods for aortic abdominal aneurysm
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
EP2897946B1 (en) 2012-09-21 2016-11-16 Bristol-Myers Squibb Company N-substituted bis(fluoroalkkyl)-1,4-benzodiazepinone compounds as notch inhibitors
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
WO2014047397A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
US9133139B2 (en) 2012-09-21 2015-09-15 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
TWI614238B (en) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof
JP2015534554A (en) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
JP2015531792A (en) 2012-09-21 2015-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Prodrugs of 1,4-benzodiazepinone compounds
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
CN105101968A (en) 2013-04-04 2015-11-25 百时美施贵宝公司 Combination therapy for the treatment of proliferative diseases
WO2015108988A2 (en) 2014-01-17 2015-07-23 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
WO2016007775A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
BR112018001480A2 (en) 2015-07-24 2018-09-11 Oncotracker Inc gamma secretase modulators for the treatment of immune system dysfunction
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
EP3407901B1 (en) 2016-01-29 2021-07-21 Massachusetts Eye & Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
AU2017268078B2 (en) 2016-05-16 2023-03-02 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
RU2757276C2 (en) 2016-12-16 2021-10-12 Пайплайн Терапьютикс, Инк. Methods for the treatment of cochlear synaptopathy
CN117357638A (en) 2017-02-17 2024-01-09 弗雷德哈钦森癌症中心 Combination therapy for the treatment of BCMA-related cancers and autoimmune disorders
DK3461819T3 (en) 2017-09-29 2020-08-10 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS
US20210290633A1 (en) 2018-07-19 2021-09-23 INSERM (Insstitut National de la Santé et de la Recherche Médicale) Combination for treating cancer
BR112022018987A2 (en) 2020-03-26 2022-11-01 Seagen Inc MULTIPLE MYELOMA TREATMENT METHODS
EP4244391A1 (en) 2020-11-16 2023-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91307A0 (en) * 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
CA2076204A1 (en) * 1991-08-16 1993-02-17 Samuel L. Graham Hiv protease inhibitors with n-terminal polyether substituents
WO1994013319A1 (en) 1992-12-16 1994-06-23 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
US5703129A (en) 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
EP0931792B1 (en) * 1998-01-27 2004-01-07 Nisshin Seifun Group Inc. Depsipeptides containing non-natural amino acids

Also Published As

Publication number Publication date
WO2001077144A1 (en) 2001-10-18
AU2001244399A1 (en) 2001-10-23
US20030100512A1 (en) 2003-05-29
US6984626B2 (en) 2006-01-10

Similar Documents

Publication Publication Date Title
GB0023983D0 (en) Therapeutic compounds
GB0008710D0 (en) Therapeutic compounds
GB0016681D0 (en) Therapeutic compounds
EP1296697A4 (en) Therapeutic agents - i
GB0012671D0 (en) Therapeutic agents
GB0003397D0 (en) Therapeutic agents
GB0004003D0 (en) Therapeutic agents
GB0009606D0 (en) Therapeutic combinations
GB0028429D0 (en) Therapy
GB0017256D0 (en) Therapeutic agents
GB0005789D0 (en) Therapeutic agents
GB0007907D0 (en) Therapeutic agents
GB0012214D0 (en) Therapeutic agents
GB0028583D0 (en) Therapeutic compounds
GB0008696D0 (en) Therapeutic agents
GB0000564D0 (en) Therapeutic agents
GB0017518D0 (en) Therapeutic agents
GB0007376D0 (en) Therapeutic agents
GB0017543D0 (en) Therapeutic agents
GB0013105D0 (en) Therapeutic compounds
GB0023982D0 (en) Therapeutic Compounds
GB0023984D0 (en) Therapeutic compounds
GB0003767D0 (en) Therapeutic compounds
GB0013648D0 (en) Therapeutic compounds
GB0013649D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)